Abstract
Antibody-based drugs are increasingly used in the clinic, and their importance is set to escalate in the coming years as more drugs in this class progress through clinical trials. Although many such drugs utilize whole antibodies, others exploit fragments, e.g., fragment antigen binding (Fab′) or single-chain fragment variable (scFv), which retain the antigen-binding specificity without the fragment crystallizable (Fc) element necessary to mediate effector functions. Antibody fragments can be advantageous for many therapeutic uses, owing to the fact that valency and half-life can be tailored through protein engineering approaches to suit the desired mechanism of action (). Furthermore, antibody fragments are more suited to expression in microbial systems, providing benefits in terms of increased scale and ease of manufacture ().
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
